Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s powerful suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections. Interested to know more?
Company Details
- Employees
- 6
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://granzabio.com/
Granza Bio (Yc W24) Questions
Granza Bio (Yc W24)'s website is https://granzabio.com/
Granza Bio (Yc W24)'s LinkedIn profile is https://www.linkedin.com/company/granza-bio-yc-w24
Granza Bio (Yc W24) has
6 employees.
View email and phone details for 6
employees at Granza Bio (Yc W24).
Granza Bio (Yc W24)'s industry is
Biotechnology Research
Granza Bio (Yc W24)'s top competitors are
Ligo Biosciences,
Ēvolvere Biosciences,
Bioescalator,
Cleancard,
Cuspai,
Tracebit,
Velorum Therapeutics (Yc W24),
Orfonyx Bio,
Ario,
Wordsmith Ai.
Granza Bio (Yc W24)'s categories are Biotechnology Research
Granza Bio (Yc W24)'s founding year is 2023
